FindTrial
Sign In

Akt Inhibitor GSK2141795

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeRecurrent Adult Acute Myeloid LeukemiaRecurrent Breast CarcinomaStage IV Breast CancerTriple-Negative Breast Carcinoma

Phase 2

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
TerminatedNCT01907815
National Cancer Institute (NCI)Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Start: 2013-10-31End: 2016-01-31Updated: 2018-04-06
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
CompletedNCT01964924
National Cancer Institute (NCI)Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma +4
Start: 2013-10-02End: 2018-04-23Updated: 2019-09-20

Related Papers

Abstract PS4-01-15: Acute and Early Circulating Tumor DNA Dynamics in Metastatic Triple-Negative Breast Cancer Targeted Therapy Phase Ib/II Clinical Trials
Clinical Cancer Research2026-02-17
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
2017-07-2220 citations